Abstract
Non-invasive prenatal testing (NIPT) for common fetal aneuploidies using circulating cell free DNA in maternal plasma has been widely adopted in clinical practice for its sensitivity and accuracy. However, the detection of subchromosomal abnormalities or monogenetic variations showed no cost-effectiveness or satisfactory accuracy. Here we describe the goodness-of-fit and graphical analysis of polymorphic sites based non-invasive prenatal testing (GGAP-NIPT) assay, which was sensitive and accurate for detecting fetal abnormalities simultaneously at the chromosomal, subchromosomal and nucleotide levels. In each sample, fetal fraction was estimated using allelic counts of polymorphic sites from normal reference chromosomal regions and each target amplicon’s genotype was determined with the aid of goodness-of-fit test. Then group of polymorphic amplicons from each target region was analyzed collectively using both statistical and graphical approaches, and fetal genetic abnormality was identified by either overall statistical model fitness or graphical characteristic allelic clusters, whereas regions containing only a single polymorphic site were analyzed using a limited number of replicates. For simulated samples, such a group analytic approach identified all aneuploidies, microdeletions or microduplications and single-gene short variations precisely. As no cross-sample comparison was performed and the relative allelic counts of each target polymorphic amplicon were internally controlled, the GGAP-NIPT assay reported here should be sensitive and accurate inherently. Therefore, the GGAP-NIPT analytical approach has the potential to detect most fetal abnormalities at the chromosomal, subchromosomal and monogenic levels with improved accuracy, facilitating the extension of NIPT to an expanded panel of genetic disorders.
Competing Interest Statement
A patent application has been filed relating to this work.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data were retrieved from NIH sra database and only computation was done on the data. Therefore, we regard that it was exempted naturally.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding statement: none.
Reformat the figures and reorganize the results
Data Availability
All data are provided upon request to gaos{at}whu.edu.cn.